Alx Oncology Is A Clinical Stagebiotechnology Company Based In South San Franciscocaliforniathecompany Is Dedicated To Developing Immuneboosting Therapies Aimed At Treating Cancer And Enhancing Patient Outcomesalx Oncology Focuses On Innovativescienceto Advanceits Oncology Treatment Pipelinethecompany S Lead Productevorpaceptalx148 Is A Cd47 Blocker That Helps Theimmunesystem Recognizeand Target Cancer Cellsit Is Currently Being Evaluated In Clinical Trials For Various Hematologic Malignancies And Solid Tumorsincluding Gastric And Breast Cancersalx Oncology Also Has Other Candidates In Its Pipelinesuch As Alta 002A Sirpitoll Likereceptor Agonist Antibody Conjugateand Alx2004An Egfr Targeted Antibody Drug Conjugatethecompany Emphasizes A Strategic Approach That Combines Its Therapies With Other Anti Cancer Agents To Improvetreatment Efficacy Alx Oncology Is Publicly Traded On Nasdaq Under Theticker Alxo And Is Focused On Advancing Its Clinical Trials Whileoptimizing Resources To Extend Its Funding Into Late2026
